Please assess the completion status of the following clinical trial:

Trial Title: Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosed with Mantle Cell Lymphoma and has had at least one chemotherapy.~2. Subjects must have measurable or evaluable disease.~3. ECOG Performance Status of 0-2.~4. Must be referred for treatment with ibrutinib.~5. Must have adequate organ function.~Exclusion Criteria:~1. Subject is pregnant.~2. Prior malignancy (except nonmelanomatous skin cancer) unless disease free for a minimum of 2 years; non-invasive conditions such as carcinoma in situ of the breast, oral cavity, or cervix are all permissible.~3. Known CNS lymphoma.~4. Prior or current treatment with certain medications. Talk to Study Contact for specifics.~5. Subject is at high risk for TLS.~6. Subject has malabsorption syndrome or other condition which may affect an enteral route of administration.~7. Subject has known contraindication or allergy to both xanthine oxidase inhibitors and rasburicase.~8. Significant history of heart disease.~9. Subject has an active infection.~10. Known active Hepatitis B or Hepatitis C.~11. A serious uncontrolled medical disorder that in the opinion of the investigator would impair the ability of the subject to receive protocol therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ABT-199 and Ibrutinib Combination (Type: EXPERIMENTAL): Participants will take ABT-199 (dose 100-400 mg) and Ibrutinib (dose 280-560 mg).

Based on this trial design, predict the completion outcome and termination type (if applicable).